Scribble

Price Momentum

PFE is trading in the middle of its 52-week range and below its 200-day simple moving average.
Price change

The price of PFE shares has decreased $0.71 since the market last closed. This is a 2.74% drop.
Closed at $25.21.

The stock has since risen $0.04 in after-hours trading.

Key terms

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $143.68B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.

Key terms

Smart score

Yesterday 11:03am ET Pfizer’s AI Upgrades and Pipeline Bets Stir Investor Hopes by TipRanks Jun 18, 2026 2:35pm ET Pfizer (PFE) Shares Sink After Surprise CFO Exit by TipRanks Jun 18, 2026 1:47pm ET Pfizer Reaffirms 2026 Outlook Amid CFO Transition by TipRanks Jun 18, 2026 1:30pm ET Pfizer reaffirms all components of FY26 guidance by TipRanks Jun 18, 2026 6:52am ET Pfizer CFO Dave Denton to step down, Cecile Guegan named interim CFO by TipRanks Jun 16, 2026 4:13pm ET Rigel closes license agreement for Veppanu by TipRanks Jun 16, 2026 1:00pm ET Option traders moderately bearish in Pfizer with shares up 0.29% by TipRanks Jun 15, 2026 12:10pm ET CMS proposes to lock in lower prices in Medicare drug price negotiation program by TipRanks Jun 15, 2026 4:40am ET Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX) by TipRanks Jun 13, 2026 11:03am ET Pfizer Pivots Hard: Obesity, Cancer Bets Tempt Investors by TipRanks Jun 12, 2026 12:33pm ET Pfizer Targets Gastric Cancer Growth With New PF-08634404 Combo Trial by TipRanks Jun 11, 2026 1:30pm ET Moderately bullish activity in Pfizer with shares up 2.21% by TipRanks Jun 11, 2026 12:32pm ET Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline by TipRanks Jun 11, 2026 9:42am ET Unusually active option classes on open June 11th by TipRanks Jun 11, 2026 6:50am ET Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) by TipRanks Jun 10, 2026 10:04pm ET Top Pfizer Executive Quietly Unloads a Chunk of Company Stock by TipRanks Jun 10, 2026 12:32pm ET Pfizer Steps Up in Obesity Race With New Mid-Stage SOLIS-1 Trial by TipRanks Jun 10, 2026 12:31pm ET Pfizer’s Next-Gen Pneumococcal Shot: What a Fresh Trial Update Means for PFE Investors by TipRanks Jun 10, 2026 7:39am ET Bernstein Remains a Hold on Pfizer (PFE) by TipRanks Jun 09, 2026 5:05pm ET Pfizer upgraded to Sector Perform from Underperform at RBC Capital by TipRanks Jun 09, 2026 5:05pm ET Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward by TipRanks Jun 09, 2026 2:35am ET Pfizer Obesity Franchise Shows Promise but Competition, Execution Risks Keep Rating at Hold and Price Target Unchanged at $26 by TipRanks Jun 08, 2026 12:33pm ET Pfizer-Backed EV-309 Trial Targets Bladder-Sparing Edge in Muscle-Invasive Cancer by TipRanks Jun 08, 2026 9:30am ET Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) by TipRanks Jun 08, 2026 8:05am ET BMO Capital Sticks to Their Buy Rating for Pfizer (PFE) by TipRanks Jun 08, 2026 7:21am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) by TipRanks Jun 08, 2026 6:51am ET Pfizer says FDA approves expanded indication for Hympavzi by TipRanks Jun 08, 2026 5:50am ET Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM) and Pfizer (PFE) by TipRanks Jun 08, 2026 5:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE), Dexcom (DXCM) and Glaukos (GKOS) by TipRanks Jun 08, 2026 4:50am ET Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Incyte (INCY) and Pfizer (PFE) by TipRanks Jun 07, 2026 6:00pm ET Pfizer presents results from Phase 2b studies of berobenatide by TipRanks

1-year income & revenue

Total revenue: $62.58B (1Y), $14.45B (Q1)

Total Revenue held flat since last year and decreased 17.69% since last quarter.
Net income: $7.77B (1Y), $2.70B (Q1)

Net Income decreased 3.1% since last year and increased 263.83% since last quarter.
Earnings per share: $1.36 (1Y), $0.47 (Q1)

EPS decreased 3.63% since last year and increased 261.77% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

PFE's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
Market cap: $143.68B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.